Latest News, Updates & Breaking Headlines
UBS has a neutral rating on Cipla with the target price cut to Rs 1,400, from Rs 1,750 earlier. Analysts said the company’s growth drivers are intact but supply headwinds weigh on near-term outlook. A healthy product pipeline to drive FY28 earnings for Cipla. However, there is a lack of near-term catalysts. They feel a…
Bengaluru: Cipla Foundation Wednesday announced a partnership with the Indian Institute of Science (IISc) to set up the Cipla Foundation Centre for Pulmonary Medicine at the Tata IISc Medical School. The facility will provide diagnostics, outpatient and inpatient care, a dedicated intensive care unit, and high-dependency services for the treatment of respiratory illnesses.The Centre for…
Several prominent Indian pharmaceutical firms, including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences, maintain substantial export operations to the USA. (AI image) Pharma stocks hit by Trump’s tariffs: Pharmaceutical stocks declined sharply by up to 5% on Friday, September 26, following US President Donald Trump’s declaration of imposing 100% tariffs…
